Search Results

PRECISE Results Published for Corindus CorPath 200 System

April 9, 2013—Giora Weisz, MD, et al published findings from the PRECISE study in the Journal of the American College of Cardiology (2013;61:1596–1600).

RIVER-PCI Shows Ranolazine Did Not Reduce Events in Patients With Incomplete Revascularization After PCI

October 13, 2015—Findings from the RIVER-PCI trial were reported at TCT 2015, the 27th annual Transcatheter Cardiovascular Therapeutics scientific symposium of the Cardiovascular Research Foundation being held October 11–15, in San Francisco, California.

PRECISE Evaluates PCI With Corindus' CorPath 200 Robotic System

May 10, 2012—At the 2012 Society for Cardiovascular Angiography and Interventions Scientific Sessions in Las Vegas, Nevada, results of PRECISE (CorPath Percutaneous Robotically Enhanced Coronary Intervention Study) were presented as a late-breaking clinical trial.

Filterlex Medical’s Captis Embolic Protection Device for TAVR Evaluated in First-in-Human Study

November 15, 2023—Filterlex Medical Ltd., a cardiovascular medical device startup based in Israel, announced the publication of a first-in-human (FIH) study of the safety and feasibility of the company’s next-generation Captis full-body embolic protection device during transcatheter aortic valve replacement (TAVR) procedures.

Corindus Announces First Results for CorPath 200 System

September 20, 2010—Corindus Vascular Robotics (Natick, MA) announced the results of the first clinical study to evaluate the safety and technical efficacy of the CorPath 200 system in delivering and manipulating coronary guidewires and stent/balloon systems in percutaneous coronary intervention (PCI) procedures.

FDA Clears Corindus Vascular Robotics CorPath 200 System for PCI

July 25, 2012—Corindus Vascular Robotics (Natick, MA) announced that the US Food and Drug Administration (FDA) granted 510(k) clearance for the CorPath 200 system to be used in percutaneous coronary interventions (PCI).

Two-Year COLOR Results Indicate PCI of NIRS-Defined Lipid-Rich Plaque is Safe

November 1, 2016—Two-year results from the COLOR trial found that percutaneous coronary intervention (PCI) on coronary artery lipid-rich plaque (LRP) detected by near-infrared spectroscopy (NIRS) was not associated with subsequent major adverse cardiac events (MACEs) compared to PCI of non-LRPs.

Data Published on Corindus CorPath 200 Robotic PCI System

April 15, 2011—Findings from a first-in-human study that aimed to evaluate the safety and feasibility of the CorPath 200 remote-controlled, robotic angioplasty system (Corindus, Inc., Natick, MA) in the delivery and manipulation of coronary guidewires, balloons, and stents in patients undergoing elective percutaneous coronary intervention (PCI) were published by Juan F. Granada, MD, et al in the Journal of the American College of Cardiology: Cardiovascular Interventions (2011;4:460–465).